| Gloribel Colon, CPL | |
|
Urb. Valle Escondido, Calle Palma Real 193, Coamo, PR 00769 | |
| (787) 216-0006 | |
| Not Available |
| Full Name | Gloribel Colon |
|---|---|
| Gender | Female |
| Speciality | Counselor |
| Location | Urb. Valle Escondido, Coamo, Puerto Rico |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780304451 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101Y00000X | Counselor | 4221 (Puerto Rico) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Gloribel Colon, CPL Urb. Valle Escondido, Calle Palma Real 193, Coamo, PR 00769 Ph: (787) 216-0002 | Gloribel Colon, CPL Urb. Valle Escondido, Calle Palma Real 193, Coamo, PR 00769 Ph: (787) 216-0006 |
News Archive
Researchers at the London School of Hygiene and Tropical Medicine in England have found that being very thin and underweight might increase the risk of women miscarrying during pregnancy.
A new study has confirmed that the drug, ivacaftor (VX-770), significantly improves lung function in some people with cystic fibrosis (CF). The results of the phase III clinical trial study, "A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation," led by Bonnie W. Ramsey, MD of Seattle Children's Research Institute and the University of Washington, were published today in the New England Journal of Medicine.
A new platform for regulating the expression of therapeutic genes, which will have major implications for gene and cell therapy, was presented at the 10th Annual Meeting of the American Society of Gene Therapy (ASGT) in Seattle.
Researchers have found a genetic variation predisposing children to six-times greater risk of developing metabolic syndrome when taking second-generation anti-psychotic medications. Metabolic syndrome is a cluster of conditions that are risk factors for cardiovascular disease.
Columbia Laboratories, Inc. today announced it completed enrollment in the PREGNANT (PROCHIEVE Extending GestatioN A New Therapy) Study last week. This randomized, double-blind, placebo controlled Phase III clinical study is evaluating the safety and efficacy of PROCHIEVE® 8% (progesterone gel) to reduce the risk of preterm birth in women with a cervical length between 1.0 and 2.0 centimeters as measured by transvaginal ultrasound at mid-pregnancy.
› Verified 7 days ago
Marta M Espada, Counselor Medicare: Not Enrolled in Medicare Practice Location: Urb Villa Madrid Calle17 W17, Coamo, PR 00769 Phone: 787-372-9496 Fax: 787-844-4130 | |
Lilianet Rodriguez, Counselor Medicare: Not Enrolled in Medicare Practice Location: D15 Calle 5, Urb Las Aguilas, Coamo, PR 00769 Phone: 787-202-1123 |